UNVC Quote, Financials, Valuation and Earnings

CVS Health has a net margin of -- compared to UNIVEC's net margin of 1.88%. UNIVEC's return on equity of -- beat CVS Health's return on equity of 7%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand CVS Health has an analysts' consensus of $79.17 which suggests that it could grow by 18.21%. Given that CVS Health has higher upside potential than UNIVEC, analysts believe CVS Health is more attractive than UNIVEC.

UNIVEC has a beta of 0.070, which suggesting that the stock is 93.018% less volatile than S&P 500. In comparison CVS Health has a beta of 0.598, suggesting its less volatile than the S&P 500 by 40.158%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 3.97% to investors and pays a quarterly dividend of $0.67 per share. UNIVEC pays -- of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UNIVEC quarterly revenues are --, which are smaller than CVS Health quarterly revenues of $94.6B. UNIVEC's net income of -- is lower than CVS Health's net income of $1.8B. Notably, UNIVEC's price-to-earnings ratio is -- while CVS Health's PE ratio is 15.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 0.22x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

First Physicians Capital Group has a net margin of -- compared to UNIVEC's net margin of --. UNIVEC's return on equity of -- beat First Physicians Capital Group's return on equity of --.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand First Physicians Capital Group has an analysts' consensus of -- which suggests that it could fall by --. Given that UNIVEC has higher upside potential than First Physicians Capital Group, analysts believe UNIVEC is more attractive than First Physicians Capital Group.

UNIVEC has a beta of 0.070, which suggesting that the stock is 93.018% less volatile than S&P 500. In comparison First Physicians Capital Group has a beta of -12.606, suggesting its less volatile than the S&P 500 by 1360.624%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. First Physicians Capital Group pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than First Physicians Capital Group quarterly revenues of --. UNIVEC's net income of -- is lower than First Physicians Capital Group's net income of --. Notably, UNIVEC's price-to-earnings ratio is -- while First Physicians Capital Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 1.40x for First Physicians Capital Group. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of -- compared to UNIVEC's net margin of 6.5%. UNIVEC's return on equity of -- beat IQVIA Holdings's return on equity of 20.79%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand IQVIA Holdings has an analysts' consensus of $197.72 which suggests that it could grow by 32.71%. Given that IQVIA Holdings has higher upside potential than UNIVEC, analysts believe IQVIA Holdings is more attractive than UNIVEC.

UNIVEC has a beta of 0.070, which suggesting that the stock is 93.018% less volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.416%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than IQVIA Holdings quarterly revenues of $3.8B. UNIVEC's net income of -- is lower than IQVIA Holdings's net income of $249M. Notably, UNIVEC's price-to-earnings ratio is -- while IQVIA Holdings's PE ratio is 20.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 1.75x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of -- compared to UNIVEC's net margin of -55.94%. UNIVEC's return on equity of -- beat SCWorx's return on equity of -80.46%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that UNIVEC has higher upside potential than SCWorx, analysts believe UNIVEC is more attractive than SCWorx.

UNIVEC has a beta of 0.070, which suggesting that the stock is 93.018% less volatile than S&P 500. In comparison SCWorx has a beta of 2.355, suggesting its more volatile than the S&P 500 by 135.489%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than SCWorx quarterly revenues of $759.7K. UNIVEC's net income of -- is lower than SCWorx's net income of -$425K. Notably, UNIVEC's price-to-earnings ratio is -- while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 0.30x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.